Cytochrome P450 2C19 Polymorphism and Antiplatelet Therapy. Who Should Really be Genotyped?

被引：4

作者：

Kassimis, George ^{[1
]}

Stavrou, Eleana F. ^{[2
]}

Alexopoulos, Dimitrios ^{[1
]}

Athanassiadou, Aglaia ^{[2
]}

机构：

[1] Patras Univ Hosp, Dept Cardiol, Patras 26500, Greece

[2] Univ Patras, Sch Med, Lab Gen Biol, GR-26110 Patras, Greece

来源：

CURRENT PHARMACEUTICAL DESIGN | 2013年 / 19卷 / 13期

关键词：

Clopidogrel; prasugrel; ticagrelor; percutaneous coronary intervention; CYP2C19; polymorphism; CLOPIDOGREL PLATELET REACTIVITY; CORONARY-ARTERY-DISEASE; PROTON PUMP INHIBITORS; OF-FUNCTION POLYMORPHISM; MAINTENANCE-DOSE CLOPIDOGREL; ACUTE MYOCARDIAL-INFARCTION; ADVERSE CLINICAL-OUTCOMES; CALCIUM-CHANNEL BLOCKERS; ASPIRIN-TREATED PATIENTS; TIMI; 38; TRIAL;

D O I：

10.2174/1381612811319130017

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

CYP2C19 is one of the principal enzymes involved in the metabolism of clopidogrel. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function. A loss-of-function allele, CYP2C19*2, is associated with an increased risk of major adverse cardiovascular events, particularly stent thrombosis, in patients with acute coronary syndromes who are receiving clopidogrel, especially among those undergoing percutaneous coronary intervention. Newer, more potent P2Y12 inhibitors like prasugrel and ticagrelor have been introduced recently in the daily clinical practice with better cardiovascular outcome in these patients. The purpose of this review article is to provide information regarding the clinical use of CYP2C19 genotyping in patients requiring antiplatelet therapy.

引用

页码：2489 / 2495

页数：7

共 50 条

[41] Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19) [J].

P. Sandwall ;

M.-W. Lo ;

B. Jonzon ;

P. Dalén ;

C. Furtek ;

M. Ritter ;

G. Alván ;

J. McCrea ;

F. Sjöqvist .

European Journal of Clinical Pharmacology, 1999, 55 :279-283

[42] Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population [J].

Zand, Negin ;

Tajik, Nader ;

Moghaddam, Alireza Salek ;

Milanian, Iraj .

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2007, 34 (1-2) :102-105

[43] Effects of Triflusal and Clopidogrel on the Secondary Prevention of Stroke Based on Cytochrome P450 2C19 Genotyping [J].

Han, Sang Won ;

Kim, Yong-Jae ;

Ahn, Seong Hwan ;

Seo, Woo-Keun ;

Yu, Sungwook ;

Oh, Seung-Hun ;

Nam, Hyo Suk ;

Choi, Hye-Yeon ;

Yoon, Sung Sang ;

Kim, Seo Hyun ;

Lee, Jong Yun ;

Lee, Jun Hong ;

Hwang, Yang-Ha ;

Lee, Kee Ook ;

Jung, Yo Han ;

Lee, Jun ;

Sohn, Sung-Il ;

Kim, Youn Nam ;

Lee, Kyung-A ;

Bushnell, Cheryl D. ;

Lee, Kyung-Yul .

JOURNAL OF STROKE, 2017, 19 (03) :356-+

[44] Influence of Cytochrome P450 2C19 Gene Variations on Pharmacokinetic Parameters of Thalidomide in Japanese Patients [J].

Matsuzawa, Naoki ;

Nakamura, Katsunori ;

Matsuda, Masayuki ;

Ishida, Fumihiro ;

Ohmori, Shigeru .

BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2012, 35 (03) :317-320

[45] The Cytochrome P450 2C19 Polymorphism Associated with Major Adverse Cardiovascular Events Risk in Kazak Patients Undergoing Percutaneous Coronary Intervention and Receiving Clopidogrel [J].

Wang, Tingting ;

Feng, Jie ;

Zhou, Liying ;

Zhao, Ting ;

Zhang, Huilan ;

Shen, Hao ;

Xu, Li ;

Sun, Li ;

Wu, Jianhua ;

Li, Hongjian ;

Yu, Luhai .

ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2023, 23 (02) :196-204

[46] Platelet Inhibition by Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients With Acute Myocardial Infarction According to Cytochrome P450 2C19 Genotype [J].

Kim, In-Suk ;

Jeong, Young-Hoon ;

Park, Yongwhi ;

Park, Ki-Soo ;

Yun, Seong-Eun ;

Park, Jeong-Rang ;

Hwang, Seok-Jae ;

Koh, Eun-Ha ;

Kwak, Choong Hwan ;

Hwang, Jin-Yong ;

Kim, Sunjoo .

JACC-CARDIOVASCULAR INTERVENTIONS, 2011, 4 (04) :381-391

[47] The impact of cytochrome P450 2C19 polymorphism on the occurrence of one-year in-stent restenosis in patients who underwent percutaneous coronary intervention: A case-match study [J].

Nozari, Younes ;

Vosooghi, Sirous ;

Boroumand, Mohammadali ;

Poorhosseini, Hamidreza ;

Nematipour, Ebrahim ;

Salarifar, Mojtaba ;

Kassaian, Seyed Ebrahim ;

Amirzadegan, Alireza ;

Alidoosti, Mohammad ;

Haji-Zeinali, Ali-Mohammad ;

Saroukhani, Sepideh .

ANATOLIAN JOURNAL OF CARDIOLOGY, 2015, 15 (05) :348-353

[48] Effect of Cytochrome P450 2C19 Polymorphism on Target Lesion Outcome After Drug-Eluting Stent Implantation in Japanese Patients Receiving Clopidogrel [J].

Nishio, Ryo ;

Shinke, Toshiro ;

Otake, Hiromasa ;

Sawada, Takahiro ;

Haraguchi, Yoko ;

Shinohara, Masakazu ;

Toh, Ryuji ;

Ishida, Tatsuro ;

Nakagawa, Masayuki ;

Nagoshi, Ryoji ;

Kozuki, Amane ;

Inoue, Takumi ;

Hariki, Hirotoshi ;

Osue, Tsuyoshi ;

Taniguchi, Yu ;

Iwasaki, Masamichi ;

Hiranuma, Noritoshi ;

Konishi, Akihide ;

Kinutani, Hiroto ;

Shite, Junya ;

Hirata, Ken-ichi .

CIRCULATION JOURNAL, 2012, 76 (10) :2348-2355

[49] Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole [J].

Ormeci, A. ;

Emrence, Z. ;

Baran, B. ;

Gokturk, S. ;

Soyer, O. M. ;

Evirgen, S. ;

Akyuz, F. ;

Karaca, C. ;

Besisik, F. ;

Kaymakoglu, S. ;

Ustek, D. ;

Demir, K. .

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (05) :879-885

[50] Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care [J].

Dietrich Rothenbacher ;

Michael M Hoffmann ;

Lutz P Breitling ;

Iris Rajman ;

Wolfgang Koenig ;

Hermann Brenner .

BMC Cardiovascular Disorders, 13

← 1 2 3 4 5 →